A new study shows an experimental heart-pump device being developed by HeartWare (HTWR +22.6%)...
A new study shows an experimental heart-pump device being developed by HeartWare (HTWR +22.6%) was able to keep more than 90% of patients alive six months after receiving the device, and worked as well as other heart-pumping devices such as one by Thoratec (THOR -20%).
From other sites
at CNBC.com (Mar 13, 2013)
at CNBC.com (Jun 17, 2011)
at CNBC.com (Mar 18, 2011)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs